Literature DB >> 15603947

Tubulin-polymerization inhibitors derived from thalidomide.

Shunsuke Inatsuki1, Tomomi Noguchi, Hiroyuki Miyachi, Sawako Oda, Toyotaka Iguchi, Masahiro Kizaki, Yuichi Hashimoto, Hisayoshi Kobayashi.   

Abstract

2-(2,6-Diisopropylphenyl)-5-hydroxy-1H-isoindole-1,3-dione (5HPP-33), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent tubulin-polymerization-inhibiting activity, comparable to that of the known tubulin-polymerization inhibitors, rhizoxin and colchicine. A major metabolite of thalidomide, 5-hydroxythalidomide, which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, also showed moderate inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15603947     DOI: 10.1016/j.bmcl.2004.10.072

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Systems Modeling of Developmental Vascular Toxicity.

Authors:  Katerine S Saili; Jill A Franzosa; Nancy C Baker; Robert G Ellis-Hutchings; Raja S Settivari; Edward W Carney; Richard Spencer; Todd J Zurlinden; Nicole C Kleinstreuer; Shuaizhang Li; Menghang Xia; Thomas B Knudsen
Journal:  Curr Opin Toxicol       Date:  2019-06-01

Review 2.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

3.  In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells.

Authors:  Min Li; Wan Sun; Ya-ping Yang; Bo Xu; Wen-yuan Yi; Yan-xia Ma; Zhong-jun Li; Jing-rong Cui
Journal:  Acta Pharmacol Sin       Date:  2008-12-22       Impact factor: 6.150

4.  A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma.

Authors:  Hirokazu Shiheido; Fukiko Terada; Noriko Tabata; Ichigo Hayakawa; Nobutaka Matsumura; Hideaki Takashima; Yoko Ogawa; Wenlin Du; Taketo Yamada; Mitsuru Shoji; Takeshi Sugai; Nobuhide Doi; Shiro Iijima; Yutaka Hattori; Hiroshi Yanagawa
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.